GE HealthCare Launches CleaRecon DL, Taking CBCT to the Next Level

GE HealthCare announces the launch of CleaRecon DL, an AI-driven solution designed to improve the quality of cone-beam computed tomography (CBCT) images, eliminating streaking caused by the pulsatile nature of blood flow in arteries and changes in contrast distribution during CBCT acquisitions for liver, prostate, neurological, and endovascular aortic repair procedures.

Harnessing deep-learning algorithms, CleaRecon DL provides clearer and more accurate imaging, enabling healthcare professionals to make better-informed decisions and improve patient care. A recent survey noted that, during clinical validation testing, CBCT images reconstructed with CleaRecon DL were clearer than conventional CBCT images in 98% of cases. The technology was also shown to improve confidence in CBCT image interpretation in 94% of cases. Having recently received U.S. FDA 510(k) clearance and a CE mark, CleaRecon DL will be available on the Allia™ platform.

“By improving image quality and reducing artifacts, CleaRecon DL can empower clinicians to perform procedures with greater precision and confidence,” said Arnaud Marie, General Manager of Interventional Solutions at GE HealthCare. Dr. Charles Nutting, an interventional radiologist at Image Guided Therapy in Denver, Colorado, said, “CleaRecon DL takes CBCT to the next level, improving our ability to perform precise interventions with less image manipulation and eliminating artifacts that have historically hindered image clarity.”